Graphical Abstract Highlights d Intestinal inflammation in UC is associated with increased anti-commensal IgG d Commensal-IgG cross-link FcgR on colonic MNPs, inducing IL-1b production d MNP FcgR A:I ratio determines magnitude of type 17 immunity and local inflammation d Identifies cellular mechanisms by which FcgRIIA H/R131 confers UC susceptibility
Correspondence
In Brief Castro-Dopico et al. find a profound induction of anti-commensal IgG in the colonic mucosa of UC patients and outline a pathway whereby FcgR receptor activation by IgG leads to IL-1b production, type 17 immunity, and the exacerbation of inflammation. Their findings reveal an important contribution of IgG-mediated inflammation in an IgAdominated organ. 
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INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic, relapsing condition with two main clinicopathological subtypes, Crohn's disease (CD) and ulcerative colitis (UC) (Kaser et al., 2010) . Susceptibility to IBD is driven by a genetic predisposition to aberrant mucosal responses to commensals (Jostins et al., 2012; McGovern et al., 2015; Neurath, 2014) and characterized by the inappropriate production of a number of pro-inflammatory cytokines and chemokines (Neurath, 2014) . Genome-wide association studies (GWASs) have provided critical insights into disease pathogenesis and implicate a FCGR2A variant that alters the binding affinity of the antibody receptor it encodes (Jostins et al., 2012) . Fc gamma receptors (FcgRs) bind to the Fc portion of immunoglobulin G (IgG), are expressed by many immune cells (including macrophages), and mediate the cellular effector functions of IgG antibodies. These cell-surface glycoproteins include activating receptors (in humans FcgRIIA, IIIA, and IIIB) and a single inhibitory receptor FcgRIIB (Nimmerjahn and Ravetch, 2008; Smith and Clatworthy, 2010) . The extent to which IgG immune complexes (ICs) activate immune cells is dependent on the relative engagement of activating or inhibitory FcgRs (the A:I ratio).
Genetic variation in FcgRs can alter the A:I ratio and influence susceptibility to a number of autoimmune diseases (Smith and Clatworthy, 2010 ). An FCGR2A single-nucleotide polymorphism (SNP) (dbSNP: rs1801274) leading to an amino acid substitution (histidine to arginine at position 131) results in a lower binding affinity for IgG, reducing the A:I ratio (Willcocks et al., 2009) . FcgRIIA-R131 is protective in UC (Jostins et al., 2012) , suggesting that IgG might play a pathogenic role in intestinal inflammation. Although in vitro studies have identified a generic increase in the production of a number of pro-inflammatory cytokines by immune cells in response to IgG (Uo et al., 2013) , there is limited insight into the cellular pathways underpinning this genetic association. Furthermore, IgG antibodies are considered less important in intestinal immunity because of the dominance of IgA at mucosal surfaces (Fagarasan, 2008) .
We found a profound induction of anti-commensal IgG and of activating FcgR signaling in the colonic mucosa in UC patients. The resulting commensal-IgG immune complexes engaged gut-resident FcgR-expressing macrophages, inducing NLRP3and reactive oxygen species (ROS)-dependent production of IL-1b and neutrophil-recruiting chemokines, and this was modulated by FCGR2A genotype. In a murine model of intestinal inflammation, manipulation of macrophage FcgR signal strength determined the magnitude of intestinal inflammation and of IL-1b-dependent induction of type 17 immunity in vivo. Our findings provide insight into the mechanisms mediating IgG-FcgRassociated inflammation in UC, which might present therapeutic targets for the treatment of UC. (legend continued on next page)
RESULTS
Anti-commensal IgG Is Associated with the Magnitude of Intestinal Inflammation
We first sought to interrogate whether there was an increase in local IgG within the gastrointestinal (GI) tract during intestinal inflammation, in line with previous reports (Baklien and Brandtzaeg, 1975; Macpherson et al., 1996; Shafir et al., 1986; Uo et al., 2013) . Analysis of published transcriptomic data of intestinal biopsies from a cohort of patients with clinically active UC demonstrated a significant enrichment of IgM and IgG heavy-chain transcripts within inflamed mucosa (Figures 1A and S1A) . Indeed, upregulation of an IGH signature (a cumulative measure of IGH expression) was specifically associated with diseased tissue in UC compared with non-diseased UC and healthy control colonic tissue ( Figure S1B ), implicating humoral responses in disease. Consistent with an increase in local commensal-specific IgG, we observed a significantly higher proportion of luminal commensals bound by IgG in UC stool samples than in household controls, in contrast to IgA-bound microbes ( Figure 1B and Table S1 ). Notably, samples with higher levels of IgG-bound commensals were found in patients with the highest disease severity scores ( Figure 1C ).
To probe this phenomenon further, we used dextran sodium sulfate (DSS), a colitogen that leads to osmotic epithelial damage, to induce barrier-breach-associated inflammation. Exposure of mice to two repeated cycles of DSS (referred to here as chronic DSS [cDSS]) induced an upregulation of IgG transcripts within the colonic mucosa ( Figure S1C ), an increase in luminal IgG ( Figure 1D ), and a modest increase in IgA, mirroring observations in human UC. Indeed, a single acute 6-day course of 2% DSS (referred to here as acute DSS [aDSS]) was sufficient to induce an increase in de novo circulating anti-commensal and anti-flagellin IgG, consistent with previous reports ) ( Figure S1D ). We also observed significantly more luminal microbes bound by IgG at day 7 and day 21 after aDSS exposure than at day 0, and the addition of paired DSS serum further increased bacterial binding by IgG ( Figure 1E ), whereas there was no significant increase in IgA-bound bacteria ( Figure S1E ). The number of luminal IgG-bound microbes correlated with colon length and colonic neutrophil infiltration (Figure 1F) , which are measures of disease severity. Indeed, the level of IgG-opsonized microbes better reflected colitis severity than that of IgA opsonization ( Figure S1F ), implicating anticommensal IgG as a determinant of the intestinal inflammatory response. Circulating anti-commensal IgG titers in serum correlated with colonic neutrophil infiltration at day 21 after aDSS exposure ( Figure S1G ). This serum IgG response was not specific to a single commensal or pathobiont but exhibited broad microbial specificity, including the probiotic Lactobacillus reuteri and the pathobiont Proteus mirabilis ( Figure 1G ), and L. reuteri IgG binding correlated most strongly with disease activity of those species tested ( Figure S1H ). Consistent with an expansion of local IgG production, we observed an increase in IgGexpressing cells within the inflamed submucosa of the colon of cDSS-treated mice ( Figure 1H ) and that B cells represented the major lymphocyte population in this setting ( Figure S1I ). By day 21 after aDSS exposure, there was a pronounced expansion of IgG + CD19 + B cells within the inflamed colonic lamina propria (LP) (Figures 1I and S1J) and colon-draining mesenteric lymph nodes (MLNs) (Figures 1J and S1M). We also observed an increase in CD138 + plasma cells within the inflamed colon ( Figure S1K ) and MLNs ( Figure S1N ), as well as an increase in the absolute numbers of IgG-expressing plasma cell at both sites (Figures S1L and S1O), indicating that although the transudation of systemic IgG might make a substantial contribution to the luminal commensal-reactive IgG, there is also de novo IgG generation locally within the GI tract. Together, these data suggest that in UC there is an increase in intestinal commensalspecific IgG, positioned to activate FcgR-expressing mucosal immune cells, and that DSS colitis provides a reasonable model for interrogating the effects of local IgG in intestinal inflammation.
Activating FcgR Signaling in Intestinal Inflammation
To address the role of FcgR signaling in intestinal inflammation, we analyzed FcgR mRNA expression in mucosal biopsies in published cohorts of UC patients. Activating FcgR gene transcripts, including FCGR2A and FCGR3A/B, were among the most differentially expressed genes in inflamed UC biopsies compared with UC in remission and non-inflamed UC biopsies and healthy control biopsies (log2 fold change [FC] > 2; Figures  2A and 2B) . In contrast, the inhibitory receptor FCGR2B was more modestly induced ( Figure 2B ), resulting in an increase in the mucosal FcgR A:I ratio ( Figure S2A ). UC-associated (B) IgG-and IgA1-and IgA2-bound SYBR green hi microbes in UC and household healthy control (HHC) stool samples were analyzed as household pairs (n = 6 per group). (C) Correlation of pooled IgG-and IgA1-and IgA2-bound bacterial levels with clinical activity index (CAI) (n = 12). (D) Murine colon luminal IgG and IgA levels following two cycles of DSS administration (cDSS) and normalized to total protein content (n = 10 per group). Medians are indicated. (E) Quantification of IgG-bound bacteria in stool after a single acute course of 6-day 2% DSS administration (aDSS) or H 2 O with (red) and without (black) paired serum pre-incubation (n = 6-9 per group). Medians are indicated. (F) Correlation of IgG-bound commensals (no serum) from pooled control and colitic mice at day 21 after aDSS with markers of colonic inflammation; length and neutrophil count (n = 20) are shown. In (D)-(F), data are pooled from two independent experiments. (G) Opsonization of commensal bacterial species with day 21 aDSS serum or healthy control serum (day 0) (n = 5 per group). Medians are indicated. Data are representative of two independent experiments. (H) Confocal image of control or inflamed colons from cDSS-treated mice (red, IgG; green, Ki67; white, phalloidin) . Data representative of three independent experiments. (I and J) Quantification of IgG-and IgA-expressing IgM À B cell subsets in murine colons (I) and colon-draining MLN (J) at day 21 after aDSS administration versus controls (day 0) (n = 5 per group). For absolute cell-count quantification plots, medians are indicated. Data are representative of three independent experiments. p values were calculated via limma with multiple correction using the Benjamini-Hochberg (BH) procedure (A), ratio paired t test (B), linear regression analysis (C and F), or the nonparametric Mann-Whitney U test (D, E, G, I, and J). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1 and Table S1 . 
Human ileal CX3CR1 + CD14 + mac. enrichment was specific to FcgRs and was not observed for other Fc receptors ( Figure S2B ), and FCGR enrichment was confirmed in a further independent UC dataset ( Figure S2C ). Furthermore, in mucosal UC biopsies taken prior to infliximab intervention (Table S2 ), elevated FCGR2A expression was associated with treatment-refractory disease ( Figure 2C ) and was predictive of subsequent resistance to tumor necrosis factor-a (TNF-a) blockade (Arijs et al., 2009a; Arijs et al., 2009b) ( Figure 2D ). The functional effect of a higher A:I ratio at a cellular level is to reduce the activation threshold, increasing the likelihood of activation upon IgG IC encounter. In keeping with this, we found an enrichment of genes associated with FcgR-mediated phagocytosis in UC biopsies compared with control biopsies (Figure 2E ), a unique pathway distinct from TLR-signaling genes (Figure S2D) . Using both a published transcriptomics dataset and confirmatory qPCR, analysis of colonic FcgR expression in cDSS-treated mice demonstrated a similar increase in FcgR transcripts ( Figure S2E ) and enrichment of FcgR activation pathway genes ( Figure 2E ). In contrast, a consistent enrichment of FcgR genes or FcgR signaling pathways in Citrobacter rodentium infection was not observed ( Figure S2F ), suggesting that our observations might be specific to DSS-induced colitis.
A number of immune cell subsets, including macrophages, dendritic cells (DCs), and neutrophils, express FcgRs. During aDSS-induced inflammation, when compared with other colonic-resident immune cells (as identified in Figure S2G ), intestinal macrophages (CD11b + CX3CR1 + Ly6C lo MHC-II + F4/ 80 + ) expressed the highest levels of both activating and inhibitory FcgRs ( Figure 2F ). In particular, FcgRIII (the murine ortholog of FcgRIIA) was highly expressed at both the transcript and protein levels (Figures 2F and 2G) . To investigate FcgR expression in the human intestine, we made use of a recently published single-cell RNA sequencing (scRNA-seq) dataset generated from human colon. Immune cell subsets were identified through canonical-marker gene expression and alignment with human peripheral-blood mononuclear cell (PBMC) singlecell transcriptomic data ( Figure S2H ). Analysis of colonic single-cell transcriptomes indicated that FCGR2A and FCER1G
were highly specific to the mononuclear phagocyte (MNP) cluster ( Figure 2H ), transcriptionally similar to circulating CD14 + classical monocytes ( Figure S2H ). Indeed, FcgRIIA was confirmed as the dominant FcgR expressed by CD14 + CX3CR1 + macrophages flow sorted from the human intestine ( Figures 2I,  S2I , and S2J). The increase in activating FCGR2A transcripts observed in colonic biopsies in UC might be due to an increase in the number of FcgR-expressing macrophages during inflammation or the upregulation of activating FcgR expression on resident macrophages. The adult intestinal macrophage pool is largely derived from circulating monocytes in homeostasis and inflammation (Bain et al., 2014) . Analysis of the CD11b + CX3CR1 + ''monocyte waterfall'' (Tamoutounour et al., 2012) demonstrated an influx of colonic monocytes and an increase in newly differentiated inflammatory Ly6C + MHC-II int macrophages and mature Ly6C lo MHC-II hi macrophages at day 7 after aDSS ( Figure 2J ). Furthermore, activating FcgR expression was augmented on these cells, increasing their A:I ratio ( Figure 2K ) and rendering them more susceptible to IgG-mediated activation. Together, these data show that the intestinal MNP system is primed to respond to the emergence of local IgG after the onset of intestinal inflammation.
Mucosal FcgR Expression Correlates with IL-1b and CXCL8
To understand the specific molecular pathways that mediate FcgR-induced intestinal inflammation in UC, we first sought to identify common inflammatory networks present in colonic biopsies across multiple UC cohorts and then to interrogate correlations with FCGR2A. Analysis of significantly enriched cytokines and chemokines (adjusted p value < 0.05) within inflamed UC mucosal biopsies revealed that IL1B and neutrophil-recruiting chemokines, including CXCL1 and CXCL8, were among the most significantly upregulated genes compared with those within controls (Figures 3A and S3A) . Of these genes, IL1B and CXCL8 correlated most strongly with FCGR2A ( Figures 3B, 3C , and S3B). We also observed a correlation between these genes and IGHG1 expression ( Figure S3C ). To further examine gene expression associations in an unbiased manner, we performed (B) FCGR enrichment in inflamed active UC (n = 15) compared with healthy control (n = 13), remission (n = 8), and non-inflamed mucosal biopsies (n = 7). Data are from GEO: GSE38713. (C) FCGR expression in colonic biopsies from UC patients refractory (n = 16) or responsive (n = 8) to infliximab treatment and healthy controls prior to treatment initiation (n = 6). Data are from GEO: GSE16879. Minimum to maximum box-and-whisker plots are shown in (B) and (C). (D) Area under the receiver operator curve (AUROC) analysis for FCGR2A expression in infliximab-refractory mucosal biopsies compared with infliximabresponsive biopsies. Data were derived as in (C). Figure S2 and Table S2 . (legend continued on next page) hierarchical clustering of all chemokine and cytokine gene transcripts and FCGR2A within these same cohorts. Strikingly, this placed IL1B in a cluster with, and adjacent to, FCGR2A ( Figures  3D and S3D) . In cDSS colitis, as in UC biopsies, Il1b was the most highly induced cytokine gene within the inflamed colon, as assessed by transcriptomic analysis, and displayed higher total expression than did other inflammatory mediators, as shown by qPCR, suggesting a dominant role for this cytokine in colitis ( Figure S3E ). Furthermore, its expression closely correlated with Fcgr3 transcript expression within whole colonic tissue by qPCR ( Figure 3E ), as did Cxcl1 and Cxcl2 (murine neutrophil-recruiting chemokines; Figure 3F ). Together, these data demonstrate that the expression of FcgRIIA and IL-1b are closely associated during colitis and raise the possibility that anti-commensal IgG might contribute to intestinal inflammation via FcgR-dependent induction of IL-1b, a Th17-polarizing cytokine (Chung et al., 2009; Shaw et al., 2012) , and neutrophilrecruiting chemokines.
Healthy controls Remission
To determine whether IgG and activating FcgR signaling and these key cytokines and chemokines might be causatively linked, we isolated human gut LP mononuclear cells (LPMCs) and stimulated them with IgG IC ex vivo to directly cross-link FcgRs. This resulted in a significant induction of IL1B and CXCL8 ( Figure 3G ). Similarly, ex vivo stimulation of murine LPMCs from aDSS-treated mice with IgG ICs resulted in an increase in IL-1b, CXCL1, and CXCL2 production ( Figure 3H ). In vivo, passive transfer of anti-commensal IgG further enhanced Il1b, Cxcl1, and Cxcl2 transcript levels within the colon after 7-day aDSS ( Figure S3F ). Together, these data support the hypothesis that commensal IgG directly drives intestinal inflammation via induction of pro-inflammatory cytokines and chemokines on resident intestinal immune cells. Intracellular cytokine staining of murine LPMCs demonstrated that CD11b + CX3CR1 + cells (population A), comprising intestinal mononuclear phagocytes (MNPs), were the dominant source of IL-1b during colitis, with a minor contribution from neutrophils ( Figure 3I ), consistent with our analysis of human colonic scRNA-seq data, showing that IL1B expression is specific to the MNP cluster ( Figure 2H ). Indeed, flow-sorted murine colonic macrophages stimulated with IgG ICs ex vivo demonstrated substantial induction of IL-1b, CXCL1, and CXCL2 expression ( Figure S3G ). Finally, we immunized and boosted C57BL/6 mice to generate high titers of circulating anti-flagellin IgG ( Figure S3H ). Transfer of this anti-flagellin-enriched serum IgG into naive IgG-deficient Rag2 À/À mice prior to aDSS significantly augmented pro-IL-1b expression by colonic CX3CR1 + MNP subsets, particularly Ly6C hi monocytes and Ly6C + MHC-II int inflammatory macrophages ( Figure 3J ) and was associated with increased weight loss ( Figures 3K and S3I) . In contrast, no difference in colonic neutrophil pro-IL-1b expression was observed, suggesting that FcgR signaling drives pro-IL-1b expression by colonic MNPs and is sufficient to induce inflammation in the absence of adaptive immune cells.
IgG-Induced IL-1b Production by Human Macrophages
We next sought to further interrogate the role of FcgR signaling in intestinal macrophage function. A cell-intrinsic effect of IgG ICs on macrophage, cytokine, and chemokine production was evident as FcgR cross-linking on flow-sorted murine CX3CR1 + Ly6C lo MHC-II hi colonic macrophages induced widespread changes in gene expression ( Figure S4A ), including 264 genes that were significantly differentially expressed in UC biopsies ( Figure 4A ). IC-induced genes were enriched in UC-relevant immune pathways, such as neutrophil chemotaxis ( Figure S4B ), and included key UC-associated cytokines such as Il1b, Il23a, and the recently characterized Osm (West et al., 2017) (Figures 4A and S4C) . Given our previous analyses demonstrating the predominance of IL1B expression in inflamed UC biopsies, that its expression is closely linked to that of FCGR2A, and that IL1B is induced in lamina propria MNP after FcgR engagement (Figure 3) , we sought to determine the molecular pathway linking FcgR cross-linking and IL-1b production. FcgR signaling resulted in the induction of genes involved in NLRP3 inflammasome priming and activation in murine colonic macrophages, including Nlrp3 ( Figures 4B  and S4D ), suggesting that IgG-associated IL-1b production by intestinal macrophages might be dependent on the NLRP3 inflammasome. Inflammasome assembly is a two-step process; ''signal 1'' is required for NLRP3 transcription, and ''signal 2'', including stimuli such as adenosine trisphosphate (ATP) and ROS, for the generation of a multimeric-complexcontaining NLRP3, ASC, and pro-caspase-1 (Schroder and Tschopp, 2010) . Priming of murine bone-marrow-derived macrophages (BMDMs) with IgG ICs, followed by ATP, resulted Figure S3 . Co-regulated genes
Ova-IC Ova (legend continued on next page) in IL-1b secretion in wild-type (WT) but not Nlrp3-deficient macrophages ( Figure 4C ). This induction was greater than either model antigen (Ova) or anti-Ova immune serum stimulation alone ( Figure S4E ). IgG IC stimulation of human monocytederived macrophages (MDMs) in the presence of a fecal commensal suspension or lipopolysaccharide (LPS) was sufficient to induce mature IL-1b secretion, an effect almost entirely abrogated by blockade of the UC-associated receptor FcgRIIA (Figures 4D and S4F ). Both IgG-IC and fecal commensals were effective in inducing IL1B transcript and pro-IL-1b protein expression ( Figure 4E ). IgG IC alone was insufficient to generate cleaved IL-1b, and although stimulation with fecal commensals resulted in the production of some mature IL-1b, only the combined stimulation of IgG ICs and fecal commensals was effective in driving substantial cleavage of pro-IL-1b to mature IL-1b ( Figure 4E ). This demonstrates that FcgR crosslinking provides a robust priming ''signal 1'' for NLRP3 inflammasome assembly. To test the extent to which IL-1b production was dependent on NLRP3 in human macrophages, we performed NLRP3 protein knockdown via the ''Trim-Away'' technique ( Figure 4F ) (Clift et al., 2017) . This substantially abrogated IgG-induced macrophage IL-1b production, as did the addition of an NLRP3 inhibitor MCC950 ( Figure 4F ). IL-1b production by human MDMs after combined stimulation of IgG ICs and commensals or LPS was also reduced by the addition of MitoTEMPO, a mitochondrial ROS inhibitor ( Figures 4G and  S4G ). Together, these data suggest that in UC, IgG-commensal ICs cross-link intestinal macrophage FcgRIIA and thus result in NLRP3-dependent IL-1b production.
To link these observations to the genetic variants associated with UC, we investigated the impact of the FcgRIIA-H/R131 SNP on macrophage IL-1b production. After stimulation with IgG ICs, we observed higher IL1B expression in MDMs obtained from subjects with the FcgRIIA-H/H131 genotype than in FcgRIIA-R/R131 macrophages ( Figure 4H ), demonstrating that this SNP, and the functional effect it confers on the FcgR A:I ratio, determines the magnitude of IL-1b induction in this context. Modeling FcgRIIA function in vivo is challenging because mice do not express FcgRIIA, and mice deficient in the orthologous receptor Fcgr3 have a complete loss of activating signaling from this receptor, which does not reflect the graded functional effect of the FcgRIIA-H/R131 SNP. Our analysis of intestinal macrophages demonstrated that FcgR expression is dominated by the single inhibitory FcgRIIB in both mice and humans and one functionally homologous low-affinity activating FcgR (FcgRIII in mice and FcgRIIA in humans) ( Figures 2G and 2I) . Therefore, we used mice with intact activating FcgR signaling but a variable FcgR A:I ratio due to absent, WT, or high-inhibitory-receptor expression, allowing interrogation of the effect of graded activating FcgR signaling strength on intestinal inflammation ( Figure 4I ). In vitro, IgG IC stimulation of BMDM from mice with a low FcgR A:I ratio due to macrophage-specific overexpression of FcgRIIB (Brownlie et al., 2008) (macrophagetransgenic [M-TG]) resulted in lower Il1b induction than in BMDM from WT mice, in contrast to BMDM from mice with a high A:I ratio due to FcgRIIB deficiency, in which Il1b induction was significantly higher than in WT mice ( Figure 4J) , in a manner analogous to the FcgRIIA-H/R131 variant (Figures 4H and 4I) . Similar results were observed for Cxcl1 and Cxcl2 ( Figure S4H ). We concluded, therefore, that these mice represent a useful model for studying the effects of differing FcgR A:I ratios in vivo.
MNP FcgR A:I Ratio Modulates Intestinal Inflammation
Compared with co-housed WT controls, Fcgr2b À/À mice subjected to aDSS had a more severe disease course, including impaired weight recovery from day 7 onward ( Figure 5A ), a time point at which there is significant induction of anti-commensal IgG ( Figure 1E) . Similarly, in an independent experiment, Fcgr2b À/À mice had more severe disease than co-housed, littermate WT controls, with Fcgr2b +/À demonstrating an intermediate phenotype ( Figure S5A ). Compared with mice reconstituted with WT bone marrow, WT mice reconstituted with Fcgr2b À/À bone marrow also showed increased susceptibly to more severe disease after exposure to aDSS ( Figure S5B ). After aDSS treatment, Fcgr2b À/À mice had increased colon and spleen weights and lymph node and spleen enlargement ( Figure S5C ), as well as marked infiltration of CD45 + cells into the colonic mucosa and submucosa in comparison with those of co-housed WT controls ( Figure 5B ). This infiltration included neutrophils ( Figure 5C ), indicative of on-going inflammation 3 weeks after exposure to aDSS. Inflamed Fcgr2b À/À colons had higher levels of Il1b transcripts ( Figure S5D ) and increased numbers of pro-IL-1b-expressing cells than WT controls ( Figure S5E ). We observed significantly higher proportions of pro-IL-1b + colonic CX3CR1 + MNPs in Fcgr2b À/À mice than in WT counterparts, particularly in newly recruited Ly6C hi monocytes and Ly6C + MHC-II + macrophages (Figures 5D, 5E , and S5F), as well as minimal pro-IL-1b expression in colonic neutrophils ( Figure S5G ). Furthermore, flowsorted colonic MHC-II + MNPs isolated from Fcgrb À/À mice with aDSS had increased Cxcl1 and Cxcl2 transcripts compared with those obtained from co-housed WT mice ( Figure 5F ), consistent with our observations in vitro.
Next, we investigated intestinal pathology in FcgRIIB-M-TG mice and confirmed increased FcgRIIB expression on colonic MNPs and that there was no difference in activating FcgRs ( Figure S5H to aDSS, in contrast to Fcgr2b À/À mice, FcgRIIB-M-TG mice had a less severe clinical disease course than did N-TG controls, as evidenced by lower weight loss ( Figure 5G) , lower colonic and MLN weight ( Figure 5H) , and a trend toward increased colon length ( Figure S5J ), but no difference in spleen size ( Figure 5H ). Colonic neutrophil infiltration was also significantly reduced in M-TG mice, consistent with improved disease resolution (Figure 5I ). There was a trend toward reduced global Il1b, Cxcl1, Cxcl2, and Ccl2 transcripts within the colons of these mice ( Figure S5K ), whereas pro-IL-1b protein was significantly reduced in intestinal CX3CR1 + MNPs in FcgRIIB-M-TG mice (Figures 5J, 5K, and S5L) .
Given that FcgRIIB modulates the B cell activation threshold, we profiled B cell class switching and commensal-reactive IgG responses in our mouse models. We observed an increase in frequency and count of class-switched B cells in the MLN and spleen of Fcgr2b À/À mice but no difference in total anticommensal IgG titer after aDSS ( Figures S5M and S5O ). We observed no significant difference in class-switched B cells between the MLN of FcgRIIB-M-TG animals at day 21 after aDSS and the MLN of N-TG mice and found similar levels of anti-commensal IgG titers between these two strains ( Figures  S5N and S5O ). Together, these data demonstrate that the differences observed in macrophage IL-1b and disease severity in mice with differing FcgR A:I ratio are not related to differences in the titers of anti-commensal IgG.
MNP FcgR A:I Ratio Modulates Intestinal Type 17 Immunity
GWASs have implicated the IL-23-IL-17A cytokine axis in both CD and UC (C atan a et al., 2015). IL-17A is expressed in healthy mucosa and contributes to intestinal homeostasis, but in excess might promote inflammation (Leppkes et al., 2009 ). Th17 cells are key producers of IL-17A within the intestine, and inhibition of these cells can reduce intestinal inflammation (Withers et al., 2016) . As well as T-cell-independent effects, a key biological effect of IL-1b is to induce the differentiation and maintenance of Th17 cells (Chung et al., 2009; Shaw et al., 2012) . Given that our data demonstrated that IgG ICs potently induce IL-1b production in intestinal macrophages in mouse and human and that IgG-IC-stimulated colonic macrophages exhibit a Th17polarizing phenotype (Figure S6A) , we sought to determine whether macrophage FcgR A:I ratio was sufficient to affect intestinal type 17 immunity. Analysis of UC biopsies identified a significant positive correlation between IL17A and FCGR2A ( Figure S6B ). Furthermore, IgG IC stimulation of inflamed colonic LPMCs resulted in the production of type-17-associated cytokines, including IL-17, granulocyte-macrophage colonystimulating factor (GM-CSF), and IL-22 ( Figure 6A ). In vivo, the magnitude of intestinal type 17 responses was determined by the FcgR A:I ratio; in Fcgr2b À/À mice, we observed an increase in colonic Il17a, Csf2, and Il22 transcripts after aDSS ( Figure 6B) , whereas there was little change in global Ifng levels ( Figure S6C ). Intracellular cytokine staining of colonic CD3ε + T cell subsets ( Figure S6D ) demonstrated a significant increase in the frequency ( Figure 6C ) and absolute cell count ( Figure 6D ) of both IL-17A + gd and ab CD4 + T cell subsets in the recovery phase of aDSS colitis. We also observed a significant increase in IL-22 production by these T cell subsets ( Figures S6E and  S6F) , although the magnitude of this response was less than for IL-17A. Globally, there was a significant correlation between Il1b and type 17 cytokine gene transcript levels in inflamed colons ( Figure S6G ), suggesting that FcgR-induced type 17 responses might be IL-1b dependent.
In support of this, augmented IL-17A production by T cells in Fcgr2b À/À mice was completely abrogated by treatment with an anti-IL-1R1-blocking antibody ( Figures 6E and S6H) , as was the increase in IL-22 ( Figure S6I ). Conversely, there were specifically fewer mucosal IL-17A-producing CD4 + ab T cells and gd T cells after aDSS in FcgRIIB-M-TG mice than in N-TG controls (Figures 6F and 6G ). Little change in colonic B cells was observed after IL-1b blockade in Fcgr2b À/À mice ( Figure S6J) ; however, there was a reduction in the severity of colitis (Figure 6H ) and colonic neutrophil infiltration ( Figure 6I ), directly implicating this pathway in detrimental immune responses driven by dysregulated FcgR signaling. (legend continued on next page)
DISCUSSION
IgG-positive cells were first described in colonic biopsies from IBD patients more than 40 years ago by Baklien and Brandtzaeg (1975) . Despite subsequent confirmation of their commensal specificity (Macpherson et al., 1996) , there has been little widespread acceptance that commensal-IgG immune complexes play a pathogenic role in UC. The subsequent identification of FCGR2A*A519G (dnSNP: rs1801274) as the most significant non-HLA genetic variant associated with UC in a Japanese GWAS (Asano et al., 2009) further supports this concept. This non-synonymous SNP results in an amino acid substitution that alters IgG binding affinity, the low-affinity variant (FcgRIIA-R131) is protective in both candidate gene studies (odds ratio 0.70-0.84) (Weersma et al., 2010; Yang et al., 2011 ) and a meta-analysis of IBD GWASs (Jostins et al., 2012) . Our study sheds light on the mechanisms underpinning these observations, demonstrating an increase in anti-commensal IgG and in the FcgR A:I ratio of mucosal immune cells in UC. The net functional effect of this is to lower the cellular activation threshold, rendering intestinal macrophages more readily activated by local IgG ICsan effect significantly offset by the low-affinity FcgRIIA-R131.
The generic effects of cross-linking FcgR on monocyte and macrophage cytokine production have been widely studied over many years by ourselves and others (Clatworthy and Smith, 2004; Clynes et al., 1999) , including in intestinal macrophages (Uo et al., 2013) , demonstrating increases in TNFa, IL-6, IL-1b, IL-10, and TL1A, to name but a few. Of these many potentially pathogenic cytokines, our study specifically identifies IL-1b as a key driver of IgG-associated inflammation in UC and reveals the molecular mechanisms underpinning this.
IL-1b correlates with disease severity in patients with IBD (Ligumsky et al., 1990; Reinecker et al., 1993) , but its role in intestinal immunity is complex. Mice deficient in IL-1b exhibit a severe non-healing disease after DSS colitis, suggesting involvement in intestinal repair (Bersudsky et al., 2014) . In contrast, IL-1b can promote chronic intestinal inflammation by inducing IL-17Asecreting innate lymphoid cells and Th17 cells (Coccia et al., 2012) . Our data identify IL-1b as a key mediator of IgG-and FcgR-associated intestinal inflammation and show that it might act to induce type 17 immunity via effects on Th17 cells, gd T cells and, potentially, group 3 innate lymphoid cells (although we did not specifically examine the latter here). We also found that IL-1b could have Th17-cell-independent effects, consistent with previous reports, for example, by promoting neutrophil and monocyte recruitment (Dinarello, 2009) . Notably, we observed IL-1b-dependent IL-17A and IL-22 production in both gd and CD4 + ab T cells, implicating both innate and adaptive T cell subsets in FcgR-driven mucosal inflammation. It will be of interest in future studies to determine the contribution of IgG-induced FcgR signaling to type 17 immunity in other models of intestinal inflammation, particularly those with a dominant role for adaptive T cells, for example, after T cell transfer into Rag À/À mice. A careful description of Th17 cytokines in this model will be of clinical relevance, given reports that isolated IL-17A blockade can exacerbate intestinal inflammation (Hueber et al., 2012) .
Although anti-commensal IgG, particularly anti-flagellin antibodies are present in CD, the association of FcgR variants with disease susceptibility is less robust than in UC (Jostins et al., 2012) . Differential effects of genetic susceptibility loci in CD and UC are well recognized. For example, genetic variants that promote intracellular pathogen recognition and clearance are associated with CD and not with UC (Abraham and Cho, 2006) . In this context, it is notable that the FcgRIIA-R131 polymorphism increases susceptibility to a number of infections (Clatworthy, 2014) and that IgG and FcgRs promote defense against mycobacterial infection (Lu et al., 2016) . Indeed, in mice, IgG and activating FcgRs are protective against the systemic spread of Citrobacter rodentium, an enteropathic bacteria (Masuda et al., 2008) . Therefore, the deleterious effects of FcgRIIA-R131 on bacterial clearance might outweigh its beneficial, anti-inflammatory effects in CD.
Our data also have therapeutic implications, identifying IgG and activating FcgR signaling as potential therapeutic targets in UC. The only randomized controlled trial to investigate the use of B cell depletion in (treatment-resistant) UC has shown no benefit but is substantially under-powered with only n = 24 subjects (Leiper et al., 2011) . Given that randomized trials of drugs licensed for IBD treatment typically require the inclusion of hundreds of patients to demonstrate efficacy (Feagan et al., 2013; Sandborn et al., 2012) , the question of whether B cell manipulation might be of benefit in UC remains to be addressed. Agents to target activating FcgR signaling might be of utility and include Syk (spleen tyrosine kinase) inhibitors, which are currently being assessed in rheumatoid arthritis (Weinblatt et al., 2010) and glomerulonephritis (Ma et al., 2017) . Alternatively, application of an FcgRIIB agonist (Bosques and Manning, 2016) in UC would potentially decrease the FcgR A:I ratio, an effect functionally analogous to the presence of the low affinity FcgRIIA-R131. Our data suggest that targeting FcgR signaling in UC would have a potential advantage over single-cytokine blockade because of its impact on the production of multiple pro-inflammatory cytokines and chemokines. Finally, it is notable that a trial of IL-1R1 blockade using anakinra in acute severe UC (ISRCTN43717130) is underway in the UK (Thomas et al., 2019) .
(E) Quantification of absolute numbers of colonic IL-17A-producing T cell subsets in co-housed WT and Fcgr2b À/À mice at day 15 after aDSS and weekly treatment with anti-IL-1R1 IgG-blocking antibody or control IgG (n = 5-7 per group). Medians are indicated. Data are representative of two independent experiments. (F) Colonic IL-17A-expressing T cell subsets in M-TG and N-TG littermate controls at day 21 after aDSS (n = 5 or 6 per group) versus controls (n = 5 or 6 per group). Data are representative of two independent experiments. (G) Quantification of absolute cell counts of colonic IL-17A-producing T cell subsets as shown in (F). Medians are indicated. (H) Weight loss of Fcgr2b À/À mice treated with control or anti-IL-1R1 IgG antibodies after aDSS treatment (n = 5-7 per group). Mean ± SEM are indicated. Data are representative of two independent experiments. (I) Colonic neutrophil infiltration in WT and Fcgr2b À/À mice treated as in (H) (n = 5-7 per group). Medians are indicated. p values were calculated with a ratio paired t test (A), the nonparametric Mann-Whitney U test (B-G and I), or a two-way ANOVA (H). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S6 .
In summary, our study sheds light on the observed genetic association of FcgRIIA polymorphisms with UC, revealing the specific molecular mechanisms by which anti-commensal IgG augment inflammation and identifying novel therapeutic targets.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Human IgG
Sigma-Aldrich Cat#I4506; RRID: AB_1163606 Fisher Scientific) for 20 min at room temperature. For biotinylated primary antibodies, secondary staining with streptavidinconjugated PE (Thermo Fisher Scientific) or APC-eFluor780 (Thermo Fisher Scientific) was performed for 20 min at 4 C at a dilution of 1:300 in PBS. For intracellular cytokine staining, cells were incubated in RPMI-1640 medium containing 10% FCS, 1X penicillinstreptomycin (both Sigma-Aldrich), and 1X Brefeldin A (Thermo Fisher Scientific) solution for 3 h at 37 C, prior to fixation and permeabilization using the Intracellular Fixation and Permeabilization Buffer Set (Thermo Fisher Scientific) as per the manufacturer's instructions. Staining was carried out for 1 h at room temperature using a combination of the following antibodies: IL-17A (TC11-18H10.1, Biolegend), IL-22 (IL22JOP, Thermo Fisher Scientific), and pro-IL-1b (NJTEN3, Thermo Fisher Scientific). All antibodies were used at a 1:100 dilution. Cell counting was performed using 123count eBeads (Thermo Fisher Scientific). Flow cytometry data collection was performed on a Fortessa cytometer (BD biosciences) and data was analyzed using FlowJo software (Tree Star Inc.). manufacturer's instructions. Library concentration was quantified by PCR using 1/10000 dilution of the library in nuclease free water (Ambion) with ROX low KAPPA library quantification kit (KAPPA Biosystems). Libraries were pooled at an equimolar concentration with up to 12 libraries per pool.
RNA sequencing and analysis
Sequencing of the libraries was carried out using a Hiseq 2500 (Illumina) on a 2x100bp sequencing run with 1 pool per flow cell lane. Sequencing was carried out at Genewiz (NJ, USA). Pooled libraries were de-multiplexed by Genewiz using Casava (Illumina) before transfer of the data to the University of Cambridge. Fastq files were trimmed of the first 3 nucleotides of the R1 strand and contaminating adaptor sequences and poor-quality bases removed (bases with a phred 33 score of < 30) using trimgalore! (Babraham bioinformatics) and quality of the resulting files was assessed using FastQC (Babraham bioinformatics). Fastq files were aligned to the mm10 genome (Downloaded from https://genome-euro.ucsc.edu/cgi-bin/hgGateway?db=mm10&redirect=manual&source=genome.ucsc.edu on 18th January 2016) using hisat2. All analysis was carried out using R version 3.2.4. Reads were counted and assigned to genes using the Featurecount function from the RSubread package. Differential expression analysis was carried out using DESeq2 using a linear model with an appropriate design matrix following the default workflow. Resulting figures were plotted using ggplot2 and heatmap.2 from the gplots package. GSEA was performed for RNA-seq data by first assigning a rank metric to each gene using the following formula:
Rank metric = 1 À P value + 1x10 À300 Á Ã ðjLFC j =LFCÞ GSEA was then run using GSEA 2.1 using the pre-ranked option with the classic setting against either gene sets from the molecular signature database or custom gene sets indicated in the text. FcgR gene lists were obtained from the Molecular Signature Database (MSigDB; http://software.broadinstitute.org/gsea/msigdb). Gene ontology analysis was carried out using TopGo. Selected populations were compared for enrichment to a gene universe which contained only genes which had a possibility of being present in both UC microarray and macrophage Ova-IC RNA-seq groups. Enriched GO terms were identified using a Fisher elim method.
Microarray
Publicly available microarray datasets were downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo/) along with appropriate chip annotation data. All analyses were carried out using R. All datasets were downloaded as raw intensity matrices. Data was normalized using RMA and limma. Probes were reduced to one probe per gene by selecting the probe with the greatest variance across the samples using the gene filter package. Differential expression was varied out using limma with an appropriate design matrix. GEO: GSE59071 (Vanhove et al., 2015) , GEO: GSE38713 (Planell et al., 2013) and GEO: GSE9452 (Olsen et al., 2009 ) datasets were used for human UC analysis, GEO: GSE16879 (Arijs et al., 2009a; Arijs et al., 2009b) for infliximab-resistant UC analysis (see also Table S2 ), GEO: GSE42768 (Breynaert et al., 2013) for analysis of murine DSS-induced colitis, and GEO: GSE49109 for C. rodentium infection analysis (Marchiando et al., 2013) . The IGH expression score was calculated as a sum of the normalized log2-transformed expression values of all IGH-containing probes in each sample. AUROC analysis was performed on normalized log2-transformed expression values of FCGR2A or the IGH expression score using GraphPad Prism 6. GSEA was performed as for RNA-seq without pre-ranking against either gene sets from the molecular signature database or custom gene sets indicated in the text.
Hierarchical clustering R and the base stats package were used for all calculations. Plots were generated using the package dendextend. For clustering analysis, the RMA normalized intensity for the genes of interest (all cytokines plus FCGR2A) were selected and a distance matrix calculated using Euclidean distance using the function ''dist.'' The samples were subsequently hierarchically clustered using the function ''hclust'' using the complete method. To define clusters, the tree was cut into k clusters at a given height based on visual interpretation of the dendrogram (typically k = 4-5). The cluster containing FCGR2A was examined further.
Single cell RNA-seq
Publicly available normal colonic mucosa single cell RNA-seq raw count data was acquired from GEO (GSE81861). Data was analyzed in R using the Seurat package. Genes with very low expression were discarded (average counts < 0.4). Data was log-normalized using global scaling, and AUROC test was used to generate a ranked list of cell type-specific genes and associated scores. Peripheral blood mononuclear cell raw count data (Zheng et al., 2017) was acquired from the 10X genomics data portal (https://support.10xgenomics.com/single-cell-gene-expression/datasets) -Donor A 68K PBMC. Data was log-normalized using global scaling in the Seurat package. Thereafter we detected highly variable genes with average log expression values between 0.01 and8 using the FindVariableGenes function in Seurat. We extracted the top 20 cell loadings after principal components analysis on the expression matrix subsetted to variable genes and generated a UMAP embedding from these loadings. We clustered the resulting k-nearest neighbor graph using Louvain clustering with default settings and annotated clusters based on marker genes defined by the AUROC test. The top 50 marker genes for each annotated cell type were used to calculate a rank-based enrichment score for single cells in the gut dataset, using the AUCell package (Aibar et al., 2017) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism software or R. For in vivo colitis experiments, comparison between experimental groups was performed using a nonparametric Mann-Whitney-U test, unless otherwise stated, and medians are indicated. For in vitro stimulation experiments, mean ± standard error of mean (SEM) are shown and a parametric Student's two-tailed t test or twoway ANOVA with Tukey's multiple comparisons test was used, unless paired samples were used, where a ratio paired t test was used. For correlations of RNA expression levels, linear regression analysis was used. For RNA-seq bioinformatics analyses, P values were calculated using the standard DESeq 2 method with multiple correction using BH. For microarray experiments, P values were calculated using the limma package with multiple correction using BH. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Sample sizes (n) for all shown data can be found in the figure legends. In vitro stimulations were performed in triplicate, unless stated, and sample sizes for in vivo experiments were determined based on initial experiments.
